<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report FEBRUARY 25, 1998
BARR LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
New York 1-9860 22-1927534
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
Two Quaker Road, P.O. Box 2900, Pomona, New York 10970-0519
(Address of principal executive offices) (Zip code)
(914) 362-1100
(Registrant's telephone number, including area code)
1
<PAGE> 2
BARR LABORATORIES, INC.
CURRENT REPORT DATED FEBRUARY 25, 1998
Item 5. Other Events
See attached Exhibit 99.1, press release announcing the Company's
response to a lawsuit filed by Invamed, Inc.
Item 7. Financial Statements and Exhibits
(c) Exhibit Number Exhibit
99.1 Registrant's February 25, 1998 press release
announcing the Company's response to a lawsuit filed
by Invamed, Inc.
2
<PAGE> 3
BARR LABORATORIES, INC.
CURRENT REPORT DATED FEBRUARY 25, 1998
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BARR LABORATORIES, INC.
Date: February 25, 1998 /S/ William T. McKee
--------------------
William T. McKee
Chief Financial Officer
3
<PAGE> 1
Exhibit 99.1
2 Quaker Road, P.O. Box 2900 N E W S R E L E A S E
Pomona, NY 10970
914-362-1100
CONTACT: Mark Corbae, 914-353-8451 EMAIL: [email protected]
BARR SAYS SUIT FILED BY INVAMED IS WITHOUT MERIT
POMONA, NY, FEBRUARY 25, 1998, -- Barr Laboratories, Inc. -- (NYSE-BRL) today
issued the following response to a lawsuit filed by Invamed, Inc. that named
Barr as a defendant in a lawsuit regarding access to the raw material source for
generic warfarin sodium anticoagulant.
- - -
Barr believes that the suit filed against it by Invamed is without merit. It is
common in the pharmaceutical industry for companies to have exclusivity
agreements with raw material providers. Barr has such an exclusive agreement
with the provider of warfarin sodium raw material.
Barr made a significant investment in identifying and qualifying a raw material
source for its warfarin sodium product. In exchange for this investment, the
Company entered into an agreement in September 1995 for exclusive production
quantities of the raw material. The Company believes that this is a valid
agreement, and that the suit is groundless.
Barr believes that this suit will have no impact on its ability to receive the
quantities of raw material necessary to meet market demand for its generic
warfarin sodium product.
Barr Laboratories, Inc. is engaged in the development, manufacture and marketing
of generic and proprietary pharmaceuticals.
[EDITOR'S ADVISORY: Barr Laboratories, Inc. news releases and corporate
information are available on Barr's home page (www.barrlabs.com) # # #
4
